PolarityTE is a brand that is dedicated to transforming the lives of patients by harnessing the body's regenerative potential. They specialize in developing personalized autologous therapies for complex wounds, where current treatment options are often limited or nonexistent. Their innovative research delves into the complex regenerative cellular biology of the skin, aiming to develop new therapies that address the needs of patients with limited treatment options.

One of their lead investigational products is SkinTE®, which has been used in over 1,200 clinical cases for patients with chronic cutaneous ulcers. PolarityTE has an accepted investigational new drug (IND) application with the FDA for SkinTE®, and they are conducting pivotal clinical studies to generate the necessary data for submission of a biologics license application (BLA). Their efforts have earned SkinTE® the designation of a Regenerative Medicine Advanced Therapy (RMAT) from the FDA.

PolarityTE focuses on addressing significant unmet needs in the realm of complex wounds, including chronic wounds like diabetic foot ulcers and venous leg ulcers, as well as acute wounds that present challenges to the healthcare system. With their dedication to research and development, PolarityTE aims to deliver groundbreaking treatments to patients in need